Good Manufacturing Practice-Derived Human Liver Stem Cell Extracellular Vesicles Attenuate Liver Fibrosis In Vivo

Area of Science:

• Hepatology
• Stem Cell Biology
• Extracellular Vesicles

Background:

• Human liver stem cells (HLSCs) are mesenchymal stromal cell (MSC)-like cells.
• HLSC-derived extracellular vesicles (HLSC-EVs) mimic the therapeutic effects of HLSCs.
• Previous research indicates HLSCs promote tissue regeneration.

Purpose of the Study:

• To evaluate the efficacy of GMP-produced HLSC-EVs in mitigating liver fibrosis in vivo.
• To assess the impact of HLSC-EVs on liver function and histology in a fibrosis model.

Main Methods:

• HLSC-EVs were produced under Good Manufacturing Practice (GMP) conditions using tangential flow filtration.
• A thioacetamide (TAA)-induced mouse model of chronic hepatic fibrosis was utilized.
• Therapeutic potential was assessed by administering HLSC-EVs to TAA-treated mice.

Main Results:

• HLSC-EV administration significantly attenuated liver fibrosis progression in TAA-treated mice.
• A notable reduction in the expression of pro-fibrotic genes was observed.
• Improved liver function was indicated by reduced plasma alanine aminotransferase and increased albumin levels.

Conclusions:

• GMP-produced HLSC-EVs possess significant antifibrotic properties.
• HLSC-EVs demonstrate therapeutic potential for chronic liver disease, improving both liver function and histology.
• This study supports the clinical applicability of HLSC-EVs in treating liver fibrosis.